Startups
Edit
AuraSense Therapeutics
http://www.aurasensetherapeutics.com/Last activity: 06.02.2015
Active - Reference to Exicure
Overview
Employees
11-50
Total raised
$31.6M
Founded date
2011
Funding Rounds 2
| Date | Series | Amount | Investors |
| Sign up to see | Sign up to see | Sign up to see | Sign up to see |
| Jun 17, 2014 | Series C round | $13.6M |
Mentions in press and media 8
| Date | Title | Description |
| Sign up to see | Sign up to see | Sign up to see |
| Jun 20, 2014 | Bill Gates Among Those Who Invested $13.6M in Chicago Biotech Startup AuraSense | Chicago-based biotech startup AuraSense Therapeutics announced this week that it has raised $13.6 million in Series C financing that includes an investment from Bill Gates. The company, which commercializes spherical nucleic acid (SNA) cons... |
| Jun 18, 2014 | AuraSense Therapeutics Inks $13.6M Series C | SKOKIE, IL, Biopharmaceutical company commercializing spherical nucleic acid (SNA) constructs as gene regulatory and immunotherapeutic agents, has announced the close of its Series C financing. >> Click here for more funding data o... |
| Jun 17, 2014 | AuraSense Therapeutics Closes $13.6M Series C Financing | AuraSense Therapeutics, a Chicago, IL-based biopharmaceutical company commercializing spherical nucleic acid (SNA™) constructs as gene regulatory and immunotherapeutic agents, closed a $13.6m Series C financing. Backers included current inv... |
| Aug 5, 2013 | AbbVie, angel investors restock nanomedicine leader Chad Mirkin’s pharma venture | The startup is developing a platform for nucleic acid-based therapeutics with applications in oncology, dermatology, neurology and for immune disorders. It says its spherical nucleic acid (SNA) conjugates overcome the greatest obstacles to ... |
| Jul 31, 2013 | AuraSense Therapeutics Closes Second Tranche of Series B Financing | AuraSense Therapeutics, a Skokie, Illinois-based biopharmaceutical company, closed the second tranche of its Series B financing. The investment, whose terms were not disclosed, adds to the initial Series B round completed in December 2011. ... |
| Dec 23, 2011 | AuraSense Therapeutics Closes Series B Financing | AuraSense Therapeutics, an Evanston, IL-based biopharmaceutical company commercializing spherical nucleic acid (SNA™) constructs as gene regulation- and chemo-therapeutics for several diseases, has closed a Series B financing of undisclosed... |
| AbbVie, angel investors restock nanomedicine leader Chad Mirkin’s pharma venture | For a Northwestern University biopharmaceutical spinoff, a second tranche of series B funding will push along preclinical development of gene-regulating therapies for multiple diseases. AuraSense Therapeutics isn’t disclosing how much was r... |
Reviews 0
FAQ about AuraSense Therapeutics
When was AuraSense Therapeutics founded?
AuraSense Therapeutics was founded in 2011.
How much funding has AuraSense Therapeutics raised?
AuraSense Therapeutics has raised $31.6M in total across 2 funding rounds.
What funding rounds has AuraSense Therapeutics raised?
Parsers VC lists 2 funding rounds of AuraSense Therapeutics, among them a Series C round of $13.6M on Jun 17, 2014.
What has the press written about AuraSense Therapeutics?
Parsers VC has collected 8 articles mentioning AuraSense Therapeutics, among them “Bill Gates Among Those Who Invested $13.6M in Chicago Biotech Startup AuraSense” (Jun 20, 2014) and “AuraSense Therapeutics Inks $13.6M Series C” (Jun 18, 2014).
Is AuraSense Therapeutics still active?
Yes, AuraSense Therapeutics is active; its latest activity on Parsers VC dates from Feb 6, 2015.